West Cancer Center & Research Institute, Germantown, TN
Ari M. Vanderwalde, Esprit Ma, Elaine Yu, Tania Szado, Richard Price, Anuj Shah, Craig S. Meyer, Ibrahim M. Abbass, Axel Grothey, Harry Staszewski, Dennis Slater, L. Johnetta Blakely, Lee S. Schwartzberg
Background: Recent approvals of targeted treatments (tx) have improved personalized care in aNSCLC. Biomarker testing is crucial for patients (pts) to receive optimal tx expeditiously. This study examined aNSCLC biomarker testing and tx patterns at OneOnc. Methods: Pts diagnosed with aNSCLC (stage ≥ IIIb) from 1/1/2015 to 5/31/2020, aged ≥ 18 years, and with ≥ 1 visit ≤ 90 days of advanced (Adv) diagnosis (Dx) were retrospectively evaluated using the nationwide Flatiron Health electronic health record derived de-identified database from selected OneOnc sites. Descriptive analyses were conducted to evaluate testing patterns for ALK, BRAF, EGFR, KRAS, PD-L1, and ROS-1 biomarkers and actionable mutation tx pattern. Results: Overall 3,860 aNSCLC pts were included, median age was 69 years, 47% females, 66% non-squamous, 29% squamous, 4% histology NOS, and 23% with ECOG performance status 0-1. Of the 3,152 (82%) pts tested for any biomarker, 64% received next-generation sequencing (NGS) vs. 36% received other biomarker tests only. Testing rates varied by biomarker: EGFR (74%), ALK (72%), ROS-1 (66%), PD-L1 (57%), BRAF (56%), KRAS (54%). Pts who received all 6 biomarker tests increased from 12% (2015), 23% (2016), 40% (2017), 41% (2018), 48% (2019) to 56% (2020). Among the tested pts, the median time from Adv Dx to the first test result was 20 days (d) and from specimen collection after Adv Dx to the first test result was 12 d. Pts tested and treated before test result available declined from 28% (2015) to 16% (2020). Of 1,207 pts with actionable mutations, 390 (32%) received tx before the test result: 35% chemotherapy (chemo) only, 28% chemo + cancer immunotherapy (CIT), and 15% CIT only. After the test result, 26% to 81% of pts received no or other tx not specific to actionable mutations [Table]. Conclusions: Findings from this study demonstrated an increase in aNSCLC biomarker testing at OneOnc over time, while 44% pts in 2020 did not receive testing on all 6 biomarkers. Some pts had tx prior to the test result, but this trend appeared to decline. Further studies are warranted to better understand the reasons for pts receiving tx that were not specific to their actionable mutations.
Stayed on original or no tx*, % | Received respective actionable mutation tx**,% | Received no or other tx, % | |
---|---|---|---|
ALK, n=74 | 14% | 48% | 38% |
EGFR, n=291 | 13% | 61% | 26% |
ROS-1, n=27 | 11% | 44% | 44% |
PD-L1, n=292 | 18% | 46% | 37% |
BRAF, n=135 | 14% | 5% | 81% |
*included: no tx, chemo ± CIT± targeted tx, enrolled in clinical trial **respective targeted tx for ALK, EGFR, ROS-1, BRAF; CIT± chemo± targeted tx for PD-L1 positive.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Charu Aggarwal
2024 ASCO Annual Meeting
First Author: Nashat Gabrail
2023 ASCO Annual Meeting
First Author: Mo Yang
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara